Skip to main content
. 2017 May 4;113(11):1351–1363. doi: 10.1093/cvr/cvx089

Figure 1.

Figure 1

LPA-mediated VIC mineralization depends on BMP2. (A) Treatment with Ki16425 prevents OxLDL-induced mineralization of VICs (n = 6) (calcium measured after 7 days). (B) VICs were treated with mineralizing medium in presence of different LPA species (n = 6). (C) VICs were treated with mineralizing medium in presence of increasing LPA 18:1 concentration (n = 6). (D–H) RUNX2, BGLAP, COL1A1, BMP2 genes (n = 6) and ALP activity (n = 6) were increased in VICs following LPA treatment (7 days). (I) Treatment with Noggin inhibits LPA-induced mineralization (n = 6). (J) BMP2 siRNA abrogates LPA-induced mineralization of VICs (n = 6). Values are mean ± SEM. OxLDL: 100 ng/mL, Ki16425: 10 µM, LPA: 10 µM, Noggin: 2.5 µM. * P < 0.05.